Get started
Theravance Biopharma, Inc.Theravance Biopharma, Inc.Theravance Biopharma, Inc.

Theravance Biopharma, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

TBPH chart


Full chart

TBPH upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪471.58 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.01 USD
Net income (FY)
‪−55.19 M‬ USD
Revenue (FY)
‪57.42 M‬ USD
Shares float
‪45.34 M‬
Beta (1Y)
0.66

Employees


Employees (FY)
99
Change (1Y)
−12 −10.81%
Revenue / Employee (1Y)
‪580.04 K‬ USD
Net income / Employee (1Y)
‪−557.51 K‬ USD

About Theravance Biopharma, Inc.


Sector
Health Technology
CEO
Rick E. Winningham
Headquarters
South San
Website
theravance.com
Founded
2013
FIGI
BBG004HK6YX1
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

TBPH news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of TBPH is 9.59 USD — it has decreased by −1.44% in the past 24 hours. Watch Theravance Biopharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Theravance Biopharma, Inc. stocks are traded under the ticker TBPH.
TBPH stock has fallen by −2.54% compared to the previous week, the month change is a −3.42% fall, over the last year Theravance Biopharma, Inc. has showed a −12.74% decrease.
We've gathered analysts' opinions on Theravance Biopharma, Inc. future price: according to them, TBPH price has a max estimate of 21.00 USD and a min estimate of 9.00 USD. Watch TBPH chart and read a more detailed Theravance Biopharma, Inc. stock forecast: see what analysts think of Theravance Biopharma, Inc. and suggest that you do with its stocks.
TBPH reached its all-time high on Jun 26, 2017 with the price of 43.44 USD, and its all-time low was 6.10 USD and was reached on Sep 15, 2021. View more price dynamics on TBPH chart.
See other stocks reaching their highest and lowest prices.
TBPH stock is 2.82% volatile and has beta coefficient of 0.66. Track Theravance Biopharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is Theravance Biopharma, Inc. there?
Today Theravance Biopharma, Inc. has the market capitalization of ‪471.58 M‬, it has decreased by −0.80% over the last week.
Yes, you can track Theravance Biopharma, Inc. financials in yearly and quarterly reports right on TradingView.
Theravance Biopharma, Inc. is going to release the next earnings report on Mar 3, 2025. Keep track of upcoming events with our Earnings Calendar.
TBPH earnings for the last quarter are −0.26 USD per share, whereas the estimation was −0.23 USD resulting in a −12.59% surprise. The estimated earnings for the next quarter are −0.20 USD per share. See more details about Theravance Biopharma, Inc. earnings.
Theravance Biopharma, Inc. revenue for the last quarter amounts to ‪16.87 M‬ USD, despite the estimated figure of ‪15.68 M‬ USD. In the next quarter, revenue is expected to reach ‪17.07 M‬ USD.
TBPH net income for the last quarter is ‪−12.70 M‬ USD, while the quarter before that showed ‪−16.53 M‬ USD of net income which accounts for 23.18% change. Track more Theravance Biopharma, Inc. financial stats to get the full picture.
No, TBPH doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 23, 2024, the company has 99.00 employees. See our rating of the largest employees — is Theravance Biopharma, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Theravance Biopharma, Inc. EBITDA is ‪−33.11 M‬ USD, and current EBITDA margin is −82.27%. See more stats in Theravance Biopharma, Inc. financial statements.
Like other stocks, TBPH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Theravance Biopharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Theravance Biopharma, Inc. technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Theravance Biopharma, Inc. stock shows the neutral signal. See more of Theravance Biopharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.